/CTIC
CTIC Stock - CTI BioPharma Corp.
Healthcare|BiotechnologyNASDAQ
$9.10+0.06%
+$0.01 (+0.06%) • Jun 23
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).79
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+14.3%upside
Target: $10.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CTIC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.00 – $9.19
TARGET (TP)$10.40
STOP LOSS$8.37
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.83
52W High$9.10
52W Low$4.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $53.95M | N/A | N/A | $3.35M | $26.29M |
| Gross Profit | $50.43M | $-161,000 | $-4,200,000 | $3.35M | $25.41M |
| Gross Margin | 93.5% | N/A | N/A | 100.0% | 96.7% |
| Operating Income | $-79,797,000 | $-95,332,000 | $-47,769,000 | $-40,711,000 | $-32,899,000 |
| Net Income | $-91,041,000 | $-99,636,000 | $-52,951,000 | $-42,317,000 | $-29,320,000 |
| Net Margin | -168.8% | N/A | N/A | -1265.1% | -111.5% |
| EPS | $-0.79 | $-1.11 | $-0.74 | $-0.73 | $-0.52 |
Company Overview
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$12
Average Target
↑ 31.9% Upside
Now
$10
Low
$12
Average
$13
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 17th 2022 | SVB Leerink | Initiation | Outperform | $13 |
| September 1st 2022 | Jefferies | Initiation | Buy | $13 |
| July 7th 2022 | Cowen | Initiation | Outperform | $10 |
Earnings History & Surprises
CTICBeat Rate
19%
Last 16 quarters
Avg Surprise
-20.5%
EPS vs Estimate
Beats / Misses
3/10
3 met exactly
Latest EPS
$-0.21
Q3 2023
EPS Surprise History
Q4 21
-18.2%
$-0.26vs$-0.22
Q4 21
No data
Q2 22
-5.7%
$-0.37vs$-0.35
Q3 22
-5.0%
$-0.21vs$-0.20
Q4 22
+13.3%
$-0.13vs$-0.15
Q1 23
-55.6%
$-0.14vs$-0.09
Q2 23
0.0%
$-0.10vs$-0.10
Q3 23
-162.5%
$-0.21vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 9, 2024 | — | — | — | — |
Q1 2024 | Mar 4, 2024 | — | — | — | — |
Q4 2023 | Nov 6, 2023 | — | — | — | — |
Q3 2023 | Aug 14, 2023 | $-0.08 | $-0.21 | -162.5% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.10 | $-0.10 | 0.0% | = MET |
Q1 2023 | Mar 6, 2023 | $-0.09 | $-0.14 | -55.6% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.15 | $-0.13 | +13.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.35 | $-0.37 | -5.7% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-0.39 | — | — |
Q4 2021 | Nov 12, 2021 | $-0.22 | $-0.26 | -18.2% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q2 2021 | Jun 1, 2021 | $-0.20 | $-0.23 | -15.0% | ✗ MISS |
Q1 2021 | Mar 17, 2021 | $-0.16 | $-0.20 | -25.0% | ✗ MISS |
Q4 2020 | Nov 10, 2020 | $-0.15 | $-0.15 | 0.0% | = MET |
Q3 2020 | Aug 6, 2020 | $-0.12 | $-0.19 | -58.3% | ✗ MISS |
Q2 2020 | May 7, 2020 | $-0.13 | $-0.20 | -53.8% | ✗ MISS |
Q1 2020 | Mar 12, 2020 | $-0.22 | $-0.14 | +36.4% | ✓ BEAT |
Q4 2019 | Nov 4, 2019 | $-0.23 | $-0.17 | +26.1% | ✓ BEAT |
Q3 2019 | Aug 1, 2019 | $-0.19 | $-0.19 | 0.0% | = MET |
Latest News
Loading news...
Frequently Asked Questions about CTIC
What is CTIC's current stock price?
CTI BioPharma Corp. (CTIC) is currently trading at $9.10 per share. The stock has moved +0.06% today.
What is the analyst price target for CTIC?
The average analyst price target for CTIC is $10.40, based on 1 analyst.
What sector is CTI BioPharma Corp. in?
CTI BioPharma Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CTIC's market cap?
CTI BioPharma Corp. has a market capitalization of $1.20 billion, making it a small-cap company.
Does CTIC pay dividends?
No, CTI BioPharma Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCBIO
Crescent Biopharma, Inc.
$11.85
Mkt Cap: $0.2B
CINC
CinCor Pharma, Inc.
$29.06
Mkt Cap: $1.3B
EQRX
EQRx, Inc.
$2.34
Mkt Cap: $1.1B
ETHZ
Ethzilla Corp.
$6.90
Mkt Cap: $0.1B
GRCL
Gracell Biotechnologies Inc.
$10.25
Mkt Cap: $0.2B
PNT
POINT Biopharma Global Inc.
$12.50
Mkt Cap: $1.3B
PSTX
Poseida Therapeutics, Inc.
$9.50
Mkt Cap: $0.9B
VECT
VectivBio Holding AG
$16.87
Mkt Cap: $1.1B
VERV
Verve Therapeutics, Inc.
$11.13
Mkt Cap: $1.0B
Explore stocks similar to CTIC for comparison